NCT06153342View on ClinicalTrials.gov

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Allergic Conjunctivitis
Interventions
DRUG

TL-925

TL-925 is an eye drop.

DRUG

Placebo

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Trial Locations (1)

01810

RECRUITING

Andover Eye Associates, Andover

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY